Trial Profile
An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of MabThera (rituximab) in combination with methotrexate in synovial tissue and in peripheral blood of patients with active rheumatoid arthritis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Roche
- 09 Apr 2022 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 15 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 17 Dec 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.